Dovitinib
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Adenoid Cystic Carcinoma of the Salivary Glands
Conditions
Recurrent Adenoid Cystic Carcinoma of the Salivary Glands, Metastatic Adenoid Cystic Carcinoma of the Salivary Glands, Salivary Gland Cancers, ACC
Trial Timeline
Nov 1, 2012 → Sep 1, 2015
NCT ID
NCT01678105About Dovitinib
Dovitinib is a phase 2 stage product being developed by Novartis for Recurrent Adenoid Cystic Carcinoma of the Salivary Glands. The current trial status is completed. This product is registered under clinical trial identifier NCT01678105. Target conditions include Recurrent Adenoid Cystic Carcinoma of the Salivary Glands, Metastatic Adenoid Cystic Carcinoma of the Salivary Glands, Salivary Gland Cancers.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01888965 | Phase 2 | Terminated |
| NCT01732107 | Phase 2 | Terminated |
| NCT01769547 | Phase 2 | Terminated |
| NCT01676714 | Phase 2 | Completed |
| NCT01753713 | Phase 2 | Completed |
| NCT01266070 | Phase 2 | Terminated |
| NCT01678105 | Phase 2 | Completed |
| NCT01719549 | Phase 2 | Completed |
| NCT01791387 | Phase 2 | UNKNOWN |
| NCT01262027 | Phase 2 | Completed |
| NCT01443481 | Phase 1 | Completed |
Competing Products
20 competing products in Recurrent Adenoid Cystic Carcinoma of the Salivary Glands